98 related articles for article (PubMed ID: 14581261)
1. Possible differences between fibrates in pharmacokinetic interactions with statins.
Ballantyne CM; Davidson MH
Arch Intern Med; 2003 Oct; 163(19):2394-5. PubMed ID: 14581261
[No Abstract] [Full Text] [Related]
2. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
Davidson MH
Expert Opin Drug Saf; 2006 Jan; 5(1):145-56. PubMed ID: 16370963
[TBL] [Abstract][Full Text] [Related]
3. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
Jamal SM; Eisenberg MJ; Christopoulos S
Am Heart J; 2004 Jun; 147(6):956-65. PubMed ID: 15199341
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic implications of HMG CoA reductase inhibitors.
White CM
Conn Med; 2000 Sep; 64(9):533-5. PubMed ID: 11055086
[No Abstract] [Full Text] [Related]
5. Dual hepatic metabolism of cerivastatin--clarifications.
Guyton JR; Dujovne CA; Illingworth DR
Am J Cardiol; 1999 Aug; 84(4):497. PubMed ID: 10468102
[No Abstract] [Full Text] [Related]
6. Rhabdomyolysis with HMG CoA reductase inhibitors: a class effect?
Langford NJ; Kendall MJ
J Clin Pharm Ther; 2001 Dec; 26(6):391-5. PubMed ID: 11722675
[No Abstract] [Full Text] [Related]
7. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
Saito M; Hirata-Koizumi M; Urano T; Miyake S; Hasegawa R
J Clin Pharm Ther; 2005 Feb; 30(1):21-37. PubMed ID: 15659001
[TBL] [Abstract][Full Text] [Related]
8. The use of statins in conjunction with protease inhibitors and in renal insufficiency.
Mikhail N; Cope D
Arch Intern Med; 2003 Jul; 163(13):1615-6; author reply 1616. PubMed ID: 12860588
[No Abstract] [Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.
Shitara Y; Sugiyama Y
Pharmacol Ther; 2006 Oct; 112(1):71-105. PubMed ID: 16714062
[TBL] [Abstract][Full Text] [Related]
10. Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients.
Launay-Vacher V; Izzedine H; Deray G
Int J Cardiol; 2005 May; 101(1):9-17. PubMed ID: 15860377
[TBL] [Abstract][Full Text] [Related]
11. [Cardiovascular system drugs. 8/12. Antilipemics--I. The statins].
Nerich V; Limat S; Woronoff-Lemsi MC
Soins; 2004 Dec; (691):53-4. PubMed ID: 15646522
[No Abstract] [Full Text] [Related]
12. Statin safety and drug interactions: clinical implications.
Bottorff MB
Am J Cardiol; 2006 Apr; 97(8A):27C-31C. PubMed ID: 16581325
[TBL] [Abstract][Full Text] [Related]
13. Pitavastatin (Livalo)--the seventh statin.
Med Lett Drugs Ther; 2010 Jul; 52(1343):57-8. PubMed ID: 20651638
[No Abstract] [Full Text] [Related]
14. The role of fibrates in a statin world.
Bloomfield HE
Arch Intern Med; 2006 Apr; 166(7):715-6. PubMed ID: 16606806
[No Abstract] [Full Text] [Related]
15. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.
Schneck DW; Birmingham BK; Zalikowski JA; Mitchell PD; Wang Y; Martin PD; Lasseter KC; Brown CD; Windass AS; Raza A
Clin Pharmacol Ther; 2004 May; 75(5):455-63. PubMed ID: 15116058
[TBL] [Abstract][Full Text] [Related]
16. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites.
Backman JT; Luurila H; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2005 Aug; 78(2):154-67. PubMed ID: 16084850
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic interactions between statins and fibrates.
Corsini A; Bellosta S; Davidson MH
Am J Cardiol; 2005 Nov; 96(9A):44K-49K; discussion 34K-35K. PubMed ID: 16291014
[TBL] [Abstract][Full Text] [Related]
18. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.
Jones PH; Davidson MH
Am J Cardiol; 2005 Jan; 95(1):120-2. PubMed ID: 15619408
[TBL] [Abstract][Full Text] [Related]
19. [Statins and their pleiotropic effects].
Galus R; Zandecki Ł; Jóźwiak J; Włodarski K
Pol Merkur Lekarski; 2008 Jun; 24(144):545-8. PubMed ID: 18702340
[TBL] [Abstract][Full Text] [Related]
20. Approximate equivalent rosuvastatin doses for temporary statin interchange programs.
Kendrach MG; Kelly-Freeman M
Ann Pharmacother; 2004; 38(7-8):1286-92. PubMed ID: 15187217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
